Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q3 2023 · 10-Q
Revenue$0.00$0.00— vs Q3 2022 Net Income-$1.59M-$1.59MN/M vs Q3 2022 EPS Diluted-$0.03-$0.03N/M vs Q3 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
-$1,588,700
N/M
Operating Cash Flowderived$483N/M ended Sep 30, 2023 · filed Jul 11, 2025 · 650 d after period end